{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:13:39Z","timestamp":1790745219582,"version":"4.1.0"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,10,2]],"date-time":"2019-10-02T00:00:00Z","timestamp":1569974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"DOI":"10.3389\/fneur.2019.01056","type":"journal-article","created":{"date-parts":[[2019,10,2]],"date-time":"2019-10-02T00:34:21Z","timestamp":1569976461000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":67,"title":["Anti-IgLON5 Disease: A Case With 11-Year Clinical Course and Review of the Literature"],"prefix":"10.3389","volume":"10","author":[{"given":"Mette Scheller","family":"Nissen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Blaabjerg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,10,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/S1474-4422(14)70051-1","article-title":"A novel non-rapid-eye movement and rapid-eye-movement parasomnia with sleep breathing disorder associated with antibodies to IgLON5: a case series, characterisation of the antigen, and post-mortem study","volume":"13","author":"Sabater","year":"2014","journal-title":"Lancet Neurol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1186\/s12974-016-0689-1","article-title":"Cellular investigations with human antibodies associated with the anti-IgLON5 syndrome","volume":"13","author":"Sabater","year":"2016","journal-title":"J Neuroinflammation."},{"key":"B3","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s00401-016-1591-8","article-title":"Neuropathological criteria of anti-IgLON5-related tauopathy","volume":"132","author":"Gelpi","year":"2016","journal-title":"Acta Neuropathol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1212\/WNL.0000000000003887","article-title":"Clinical manifestations of the anti-IgLON5 disease","volume":"88","author":"Gaig","year":"2017","journal-title":"Neurology."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e385","DOI":"10.1212\/NXI.0000000000000385","article-title":"IgLON5 antibody: neurological accompaniments and outcomes in 20 patients","volume":"4","author":"Honorat","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B6","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1097\/RLU.0000000000001339","article-title":"Serial 18F-FDG PET\/CT findings in a patient with IgLON5 encephalopathy","volume":"41","author":"Zhang","year":"2016","journal-title":"Clin Nucl Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jneuroim.2016.09.012","article-title":"Chorea and parkinsonism associated with autoantibodies to IgLON5 and responsive to immunotherapy","volume":"300","author":"Haitao","year":"2016","journal-title":"J Neuroimmunol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jneuroim.2017.05.019","article-title":"Autoimmune encephalitis associated with vitiligo?","volume":"310","author":"Haitao","year":"2017","journal-title":"J Neuroimmunol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e302","DOI":"10.1212\/NXI.0000000000000302","article-title":"Isolated dysphagia as initial sign of anti-IgLON5 syndrome","volume":"4","author":"Schroder","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B10","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1212\/WNL.0000000000005859","article-title":"IgLON5: a case with predominant cerebellar tau deposits and leptomeningeal inflammation","volume":"91","author":"Schoberl","year":"2018","journal-title":"Neurology."},{"key":"B11","doi-asserted-by":"publisher","first-page":"e383","DOI":"10.1212\/NXI.0000000000000383","article-title":"IgLON5 disease responsive to immunotherapy","volume":"4","author":"Bonello","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1212\/WNL.0000000000005679","article-title":"IgLON5-mediated neurodegeneration is a differential diagnosis of CNS Whipple disease","volume":"90","author":"Morales-Briceno","year":"2018","journal-title":"Neurology."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e1659","DOI":"10.1212\/WNL.0000000000006388","article-title":"Teaching video neuroimages: facial myokymia and myorhythmia in anti-IgLON5 disease: the bitten lip","volume":"91","author":"Vetter","year":"2018","journal-title":"Neurology."},{"key":"B14","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3233\/JND-170259","article-title":"Expanding the clinical spectrum of IgLON5-syndrome","volume":"4","author":"Wenninger","year":"2017","journal-title":"J Neuromuscul Dis."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e485","DOI":"10.1212\/NXI.0000000000000485","article-title":"Subacute encephalitis with recovery in IgLON5 autoimmunity","volume":"5","author":"Ramanan","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1111\/cns.13038","article-title":"Motor neuron disease-like phenotype associated with anti-IgLON5 disease","volume":"24","author":"Tao","year":"2018","journal-title":"CNS Neurosci Ther."},{"key":"B17","doi-asserted-by":"publisher","first-page":"329","DOI":"10.3389\/fneur.2018.00329","article-title":"IgLON5-associated encephalitis with atypical brain magnetic resonance imaging and cerebrospinal fluid changes","volume":"9","author":"Montagna","year":"2018","journal-title":"Front Neurol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jneuroim.2014.08.027","article-title":"Autoantibodies against IgLON5: two new cases","volume":"275","author":"Bahtz","year":"2014","journal-title":"J Neuroimmunol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s00415-019-09221-3","article-title":"Intravenous immunoglobulins as first-line therapy for IgLON5 encephalopathy","volume":"266","author":"Logmin","year":"2019","journal-title":"J Neurol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s11910-018-0848-0","article-title":"The sleep disorder in anti-lgLON5 disease","volume":"18","author":"Gaig","year":"2018","journal-title":"Curr Neurol Neurosci Rep."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.1111\/ene.13566","article-title":"IgLON5 antibodies are infrequent in patients with isolated sleep apnea","volume":"25","author":"Hasselbacher","year":"2018","journal-title":"Eur J Neurol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.parkreldis.2017.03.002","article-title":"IgLON5 autoimmunity tested negative in patients with progressive supranuclear palsy and corticobasal syndrome","volume":"38","author":"Mangesius","year":"2017","journal-title":"Parkinsonism Relat Disord."},{"key":"B23","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.str.2019.03.004","article-title":"A proteomic screen of neuronal cell-surface molecules reveals IgLONs as structurally conserved interaction modules at the synapse","volume":"27","author":"Ranaivoson","year":"2019","journal-title":"Structure"},{"key":"B24","doi-asserted-by":"publisher","first-page":"s1304","DOI":"10.2741\/1214","article-title":"Neural GPI-anchored cell adhesion molecules","volume":"8","author":"Karagogeos","year":"2003","journal-title":"Front Biosci."},{"key":"B25","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/0896-6273(95)90034-9","article-title":"The limbic system-associated membrane protein is an Ig superfamily member that mediates selective neuronal growth and axon targeting","volume":"15","author":"Pimenta","year":"1995","journal-title":"Neuron."},{"key":"B26","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1002\/cbf.1600","article-title":"IgLON cell adhesion molecules regulate synaptogenesis in hippocampal neurons","volume":"27","author":"Hashimoto","year":"2009","journal-title":"Cell Biochem Funct."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1176934318775081","DOI":"10.1177\/1176934318775081","article-title":"Molecular evolution and functional divergence of the IgLON family","volume":"14","author":"Kubick","year":"2018","journal-title":"Evol Bioinformatics Online."},{"key":"B28","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1086\/518720","article-title":"A genomewide screen for late-onset Alzheimer disease in a genetically isolated Dutch population","volume":"81","author":"Liu","year":"2007","journal-title":"Am J Hum Genet."},{"key":"B29","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3389\/fnmol.2018.00008","article-title":"Altered expression profile of IgLON family of neural cell adhesion molecules in the dorsolateral prefrontal cortex of schizophrenic patients","volume":"11","author":"Karis","year":"2018","journal-title":"Front Mol Neurosci."},{"key":"B30","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3389\/fimmu.2018.00097","article-title":"A new classification system for IgG4 autoantibodies","volume":"9","author":"Koneczny","year":"2018","journal-title":"Front Immunol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3233\/JAD-170189","article-title":"Microglial and neuronal TDP-43 pathology in anti-IgLON5-related tauopathy","volume":"59","author":"Cagnin","year":"2017","journal-title":"J Alzheimers Dis."},{"key":"B32","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1002\/mds.25926","article-title":"Friend or foe? IgLON5 antibodies in a novel tauopathy with prominent sleep movement disorder, ataxia, and chorea","volume":"29","author":"Balint","year":"2014","journal-title":"Mov Disord."},{"key":"B33","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1002\/mds.26608","article-title":"Dystonia, lower limb stiffness, and upward gaze palsy in a patient with IgLON5 antibodies","volume":"31","author":"Bruggemann","year":"2016","journal-title":"Mov Disord."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.2967\/jnumed.116.184333","article-title":"Diagnostic value of 18F-FDG PET\/CT versus MRI in the setting of antibody specific autoimmune encephalitis","volume":"58","author":"Solnes","year":"2017","journal-title":"J Nucl Med"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fneur.2019.01056\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,2]],"date-time":"2019-10-02T00:34:23Z","timestamp":1569976463000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fneur.2019.01056\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,2]]},"references-count":34,"alternative-id":["10.3389\/fneur.2019.01056"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2019.01056","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,2]]},"article-number":"1056"}}